Atalaya Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Atalaya Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-150,000	Closed	-$1.55M	–	151
2023 Q2	$1.55M	Hold	150,000	–	–	0.75%	26
2023 Q1	$1.52M	Hold	150,000	–	–	0.48%	48
2022 Q4	$1.49M	Hold	150,000	–	–	0.27%	79
2022 Q3	$1.46M	Hold	150,000	–	–	0.2%	112
2022 Q2	$1.46M	Hold	150,000	–	–	0.17%	137
2022 Q1	$1.46M	Hold	150,000	–	–	0.15%	147
2021 Q4	$1.45M	Hold	150,000	–	–	0.14%	146
2021 Q3	$1.45M	Buy	+150,000	New	+$1.46M	0.22%	96

Other funds holding NKGN

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AIMCA

Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Atalaya Capital Management's NKGN Position: Q3 2023 in Review

Atalaya Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 150,000 shares — an estimated $1.55M sold.

Atalaya Capital Management first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $1.55M in Q2 2023. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

Atalaya Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Atalaya Capital Management sold 150,000 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $1.55M.
Atalaya Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Atalaya Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $1.55M in Q2 2023.
13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on Atalaya Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.